Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12086669 | 0.94 | CXCR1 (1.00) | CXCR1CXCR2 | |
| SCHEMBL12262829 | 0.92 | CXCR1 (0.86) | CXCR1CXCR2 | |
| SCHEMBL12262983 | 0.90 | CXCR1 (0.80) | CXCR1CXCR2 | |
| SCHEMBL12262984 | 0.90 | CXCR1 (1.00) | CXCR1CXCR2 | |
| SCHEMBL12262942 | 0.89 | CXCR1 (0.79) | CXCR1CXCR2 | |
| SCHEMBL12262944 | 0.89 | CXCR1 (1.00) | CXCR1CXCR2 | |
| SCHEMBL14453604 | 0.89 | CXCR2 (0.81) | CXCR1CXCR2 | |
| SCHEMBL12626164 | 0.87 | CXCR2 (0.78) | CXCR1CXCR2 | |
| SCHEMBL12086747 | 0.86 | CXCR2 (1.00) | CXCR1CXCR2 | |
| SCHEMBL12262977 | 0.86 | CXCR2 (1.00) | CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155756-A1 | Treatment of chemokine mediated diseases | CXCR3, ACKR3, CCL11 | CXCR1 5/4885CXCR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.